Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 5
Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies
A panel of medical experts explore how to evaluate and adjust rheumatoid arthritis treatment by adhering to ACR guidelines for conventional synthetic DMARDs and advanced therapies, focusing on optimizing patient care and treatment outcomes.
Video content above is prompted by the following:
Conventional synthetic disease-modifying antirheumatic drugs (csDMARDS), including methotrexate, are generally considered first-line treatment.The American College of Rheumatology (ACR) Guidelines recommend monitoring disease activity at least every 3 months, based on the safety and efficacy of the chosen therapy, and adjusting therapy as needed in the absence of improvement. For patients with ongoing active disease or with poor prognostic factors, combination DMARD therapy or advanced treatment with a biologic agent is typically initiated.
In your practice, how do you assess rheumatoid arthritis disease activity and therapeutic response?
